Zhiquan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhiquan Liu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Siyu Chen
Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Palo Alto, CA 94304, USA
9 shared publications- Yang Sun
Department of Ophthalmology, Stanford University School of Medicine
7 shared publications - Liangxue Lai
Institute of Development and Regeneration, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China
5 shared publications - Zhanjun Li
Key Laboratory of Zoonosis Research, Ministry of Education, College of Animal Sciences, Jilin University, Changchun, China
5 shared publications Mao Chen
Key Laboratory of Zoonosis Research, Ministry of Education, College of Animal Science, Jilin University, Changchun, 130062 China
4 shared publicationsQing Wang
Department of Ophthalmology, Stanford University School of Medicine
4 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Defective neuronal differentiation in Lowe syndrome is associated with mitochondrial dysfunction and impaired cilia-related Sonic Hedgehog signaling
Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an Ocrl knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, our findings support a model in which OCRL deficiency is associated with mitochondrial dysfunction, increased oxidative stress, altered neural lineage balance, and reduced Hedgehog pathway activity, providing a framework for understanding these interconnected phenotypes.
- 18 September 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessDefective neuronal differentiation in Lowe syndrome is associated with mitochondrial dysfunction and impaired cilia-related Sonic Hedgehog signaling
Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an Ocrl knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, our findings support a model in which OCRL deficiency is associated with mitochondrial dysfunction, increased oxidative stress, altered neural lineage balance, and reduced Hedgehog pathway activity, providing a framework for understanding these interconnected phenotypes.
- Open Access
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77704
CRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome
Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5âphosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutationâagnostic OCRL DNA augmentation therapy and a patientâspecific CRISPRâmediated gene correction strategy. The results showed that AAV2âOCRL demonstrated the highest transduction efficiency in patient iPSCâderived trabecular meshwork models (iHTM) among the three AAVâOCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPRâbased gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSCâderived trabecular meshwork cell models. Furthermore, RNAâsequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECMâadhesionâcytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndromeâassociated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPRâbased gene editing in patientâderived ocular models and position AAV2âOCRL as a leading therapeutic candidate for Lowe syndrome.
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77704
Open AccessCRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome
Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5âphosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutationâagnostic OCRL DNA augmentation therapy and a patientâspecific CRISPRâmediated gene correction strategy. The results showed that AAV2âOCRL demonstrated the highest transduction efficiency in patient iPSCâderived trabecular meshwork models (iHTM) among the three AAVâOCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPRâbased gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSCâderived trabecular meshwork cell models. Furthermore, RNAâsequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECMâadhesionâcytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndromeâassociated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPRâbased gene editing in patientâderived ocular models and position AAV2âOCRL as a leading therapeutic candidate for Lowe syndrome.
- Open Access
- 10 August 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33  (9) , 1553-1566.e4
TIGRa: An ultra-compact programmable activator enabling multiplexed and efficient gene regulation
- 10 August 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33  (9) , 1553-1566.e4
Open AccessTIGRa: An ultra-compact programmable activator enabling multiplexed and efficient gene regulation
- Open Access
- 23 July 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Defective Neuronal Differentiation in Lowe Syndrome is Associated with Mitochondrial Dysfunction and Impaired Cilia-related Sonic Hedgehog Signaling
Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an OCRL knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, we propose that mitochondrial dysfunction-induced oxidative stress acts as a central mediator linking OCRL loss to altered cell fate and disrupted Shh signaling, providing a unifying framework for these phenotypes.
- 23 July 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessDefective Neuronal Differentiation in Lowe Syndrome is Associated with Mitochondrial Dysfunction and Impaired Cilia-related Sonic Hedgehog Signaling
Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an OCRL knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, we propose that mitochondrial dysfunction-induced oxidative stress acts as a central mediator linking OCRL loss to altered cell fate and disrupted Shh signaling, providing a unifying framework for these phenotypes.
- Open Access
- 2 June 2025
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4  (6) , pgaf168
Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPRâCas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.
- 2 June 2025
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4  (6) , pgaf168
Open AccessGene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPRâCas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
Precise Correction of the Pde6b -L659P Mutation Causing Retinal Degeneration with Minimum Bystander Editing by Advanced Genome Editing Tools
Recently developed base editing (BE), prime editing (PE), and click editing (CE) technologies enable precise and efficient genome editing with minimal risk of double-strand breaks and associated toxicity. However, their effectiveness in correcting real disease-causing mutations has not been systematically compared. Here, we aim to evaluate the potential of BE, PE, and CE technologies in rescuing the retinal degeneration-causing Pde6b (c.1976T>C, p.L659P) mutation. This site is prone to bystander effects, making it an ideal model for comparing the editing outcomes of these 3 novel technologies, particularly their editing precision. We optimized BE, PE, and CE systems in vitro using Pde6b -L659P cell models and compared their editing via deep sequencing. BE and PE had similar efficiency, but PE was the most precise, minimizing bystander edits. CE had lower efficiency and higher indel rates, needing further optimization. Using the optimal PE system for in vivo electroporation in Pde6b -L659P mice, we achieved 12.4% targeted repair with high precision, partially rescuing retinal degeneration. This study demonstrates proof of concept for the precise correction of the Pde6b -L659P mutation causing retinal degeneration using BE, PE, and CE tools. The findings offer valuable insights into the future optimization of precision gene editing techniques and their potential translational applications.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
Open AccessPrecise Correction of the Pde6b -L659P Mutation Causing Retinal Degeneration with Minimum Bystander Editing by Advanced Genome Editing Tools
Recently developed base editing (BE), prime editing (PE), and click editing (CE) technologies enable precise and efficient genome editing with minimal risk of double-strand breaks and associated toxicity. However, their effectiveness in correcting real disease-causing mutations has not been systematically compared. Here, we aim to evaluate the potential of BE, PE, and CE technologies in rescuing the retinal degeneration-causing Pde6b (c.1976T>C, p.L659P) mutation. This site is prone to bystander effects, making it an ideal model for comparing the editing outcomes of these 3 novel technologies, particularly their editing precision. We optimized BE, PE, and CE systems in vitro using Pde6b -L659P cell models and compared their editing via deep sequencing. BE and PE had similar efficiency, but PE was the most precise, minimizing bystander edits. CE had lower efficiency and higher indel rates, needing further optimization. Using the optimal PE system for in vivo electroporation in Pde6b -L659P mice, we achieved 12.4% targeted repair with high precision, partially rescuing retinal degeneration. This study demonstrates proof of concept for the precise correction of the Pde6b -L659P mutation causing retinal degeneration using BE, PE, and CE tools. The findings offer valuable insights into the future optimization of precision gene editing techniques and their potential translational applications.
- Open Access
- 19 September 2024
- Published by Wiley in Advanced Science
- Vol. 11  (42) , e2405628
Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing
Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMPâspecific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adenoâassociated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proofâofâconcept demonstration for the treatment of Pde6aârelated retinal degeneration using BE and PE systems.
- 19 September 2024
- Published by Wiley in Advanced Science
- Vol. 11  (42) , e2405628
Open AccessEfficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing
Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMPâspecific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adenoâassociated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proofâofâconcept demonstration for the treatment of Pde6aârelated retinal degeneration using BE and PE systems.
- Open Access
- 1 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1-11
Inhibition of base editors with anti-deaminases derived from viruses
Cytosine base editors (CBEs), combining cytidine deaminases with the Cas9 nickase (nCas9), enable targeted C-to-T conversions in genomic DNA and are powerful genome-editing tools used in biotechnology and medicine. However, the overexpression of cytidine deaminases in vivo leads to unexpected potential safety risks, such as Cas9-independent off-target effects. This risk makes the development of deaminase off switches for modulating CBE activity an urgent need. Here, we report the repurpose of four virus-derived anti-deaminases (Ades) that efficiently inhibit APOBEC3 deaminase-CBEs. We demonstrate that they antagonize CBEs by inhibiting the APOBEC3 catalytic domain, relocating the deaminases to the extranuclear region or degrading the whole CBE complex. By rationally engineering the deaminase domain, other frequently used base editors, such as CGBE, A&CBE, A&CGBE, rA1-CBE and ABE8e, can be moderately inhibited by Ades, expanding the scope of their applications. As a proof of concept, the Ades in this study dramatically decrease both Cas9-dependent and Cas9-independent off-target effects of CBEs better than traditional anti-CRISPRs (Acrs). Finally, we report the creation of a cell type-specific CBE-ON switch based on a microRNA-responsive Ade vector, showing its practicality. In summary, these natural deaminase-specific Ades are tools that can be used to regulate the genome-engineering functions of BEs.
- 1 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1-11
Open AccessInhibition of base editors with anti-deaminases derived from viruses
Cytosine base editors (CBEs), combining cytidine deaminases with the Cas9 nickase (nCas9), enable targeted C-to-T conversions in genomic DNA and are powerful genome-editing tools used in biotechnology and medicine. However, the overexpression of cytidine deaminases in vivo leads to unexpected potential safety risks, such as Cas9-independent off-target effects. This risk makes the development of deaminase off switches for modulating CBE activity an urgent need. Here, we report the repurpose of four virus-derived anti-deaminases (Ades) that efficiently inhibit APOBEC3 deaminase-CBEs. We demonstrate that they antagonize CBEs by inhibiting the APOBEC3 catalytic domain, relocating the deaminases to the extranuclear region or degrading the whole CBE complex. By rationally engineering the deaminase domain, other frequently used base editors, such as CGBE, A&CBE, A&CGBE, rA1-CBE and ABE8e, can be moderately inhibited by Ades, expanding the scope of their applications. As a proof of concept, the Ades in this study dramatically decrease both Cas9-dependent and Cas9-independent off-target effects of CBEs better than traditional anti-CRISPRs (Acrs). Finally, we report the creation of a cell type-specific CBE-ON switch based on a microRNA-responsive Ade vector, showing its practicality. In summary, these natural deaminase-specific Ades are tools that can be used to regulate the genome-engineering functions of BEs.
- Open Access
- 11 June 2019
- Published by Springer Nature in Cell Discovery
- Vol. 5  (1) , 1-4
Efficient and precise base editing in rabbits using human APOBEC3A-nCas9 fusions
- 11 June 2019
- Published by Springer Nature in Cell Discovery
- Vol. 5  (1) , 1-4
Open AccessEfficient and precise base editing in rabbits using human APOBEC3A-nCas9 fusions
- Open Access
- 9 May 2019
- Published by Wiley in The FASEB Journal
- Vol. 33  (8) , 9210-9219
Improved base editor for efficient editing in GC contexts in rabbits with an optimized AIDâCas9 fusion
Cytidine base editors, which are composed of a cytidine deaminase fused to clustered regularly interspaced short palindromic repeat (CRISPR)âassociated protein 9 (Cas9) nickase, enable the efficient conversion of the C¡G base pair to T¡A in various organisms. However, the currently used rat apolipoprotein B mRNAâediting enzyme, catalytic polypeptide 1(rA1)âbased BE3 is often inefficient in target Cs that are immediately downstream of a G (GC context). Here, we observed that, with an 11ânt editing window, an optimized activationâinduced cytidine deaminase (AID)âCas9 fusion can efficiently convert C to T in a variety of sequence contexts in rabbits. Strikingly, the enhanced AIDâCas9 fusion (eAIDâBE4max) has significant effectiveness of inducing Tyr p.R299H mutation in GC contexts (from 16.67 to 83.33%) in comparison with BE3 in founder rabbits. Furthermore, the engineered AIDâCas9 variants were produced with reduced bystander activity [eAID (N51G)âBE4max] and increased genomeâtargeting scope (eAIDâNGâBE4max). Overall, this work provides a series of improved tools that were generated using optimized AIDâCas9 fusions and associated engineered variants that can be used for efficient and versatile CâtoâT base editing, especially in GC contexts.âLiu, Z., Shan, H., Chen, S., Chen, M., Zhang, Q., Lai, L., Li, Z. Improved base editor for efficient editing in GC contexts in rabbits with an optimized AIDâCas9 fusion. FASEB J. 33, 9210â9219 (2019). www.fasebj.org
- 9 May 2019
- Published by Wiley in The FASEB Journal
- Vol. 33  (8) , 9210-9219
Open AccessImproved base editor for efficient editing in GC contexts in rabbits with an optimized AIDâCas9 fusion
Cytidine base editors, which are composed of a cytidine deaminase fused to clustered regularly interspaced short palindromic repeat (CRISPR)âassociated protein 9 (Cas9) nickase, enable the efficient conversion of the C¡G base pair to T¡A in various organisms. However, the currently used rat apolipoprotein B mRNAâediting enzyme, catalytic polypeptide 1(rA1)âbased BE3 is often inefficient in target Cs that are immediately downstream of a G (GC context). Here, we observed that, with an 11ânt editing window, an optimized activationâinduced cytidine deaminase (AID)âCas9 fusion can efficiently convert C to T in a variety of sequence contexts in rabbits. Strikingly, the enhanced AIDâCas9 fusion (eAIDâBE4max) has significant effectiveness of inducing Tyr p.R299H mutation in GC contexts (from 16.67 to 83.33%) in comparison with BE3 in founder rabbits. Furthermore, the engineered AIDâCas9 variants were produced with reduced bystander activity [eAID (N51G)âBE4max] and increased genomeâtargeting scope (eAIDâNGâBE4max). Overall, this work provides a series of improved tools that were generated using optimized AIDâCas9 fusions and associated engineered variants that can be used for efficient and versatile CâtoâT base editing, especially in GC contexts.âLiu, Z., Shan, H., Chen, S., Chen, M., Zhang, Q., Lai, L., Li, Z. Improved base editor for efficient editing in GC contexts in rabbits with an optimized AIDâCas9 fusion. FASEB J. 33, 9210â9219 (2019). www.fasebj.org